1. Background
2. Objectives
3. Methods
3.1. Study Subjects
| Characteristics | Healthy Subjects (n = 170) | Clearance Subjects (n = 199) | Chronic HBV Infection Subjects (n = 305) | ||
|---|---|---|---|---|---|
| CHB (n = 169) | LC (n = 68) | HCC (n = 68) | |||
| Gender | |||||
| Malea | 77 (45.3) | 94 (47.2) | 105 (62.1) | 53 (77.9) | 58 (85.3) |
| Femalea | 93 (54.7) | 105 (52.8) | 64 (37.9) | 15 (22.1) | 10 (14.7) |
| Ageb | 45.5 ± 10.1 | 45.4 ± 11.3 | 34.1 ± 9.7 | 52.1 ± 10.9 | 56.2 ± 12.2 |
| HBsAg (-/+) | 170/0 | 199/0 | 0/169 | 0/68 | 0/68 |
| HBsAb (-/+) | 170/0 | 0/199 | 169/0 | 68/0 | 68/0 |
| HBeAg (-/+) | 170/0 | 199/0 | 59/110 | 50/18 | 49/19 |
| HBeAb (-/+) | 170/0 | 199/0 | 110/59 | 18/50 | 19/49 |
| HBcAb (-/+) | 170/0 | 0/199 | 0/169 | 0/68 | 0/68 |
Abbreviations: CHB, Chronic Hepatitis B; HCC, Heptocellular Carcinoma; LC, Liver Cirrhosis.
aValues are expressed as No. (%).
bValues are expresse as Mean ± SD.
3.2. SNPs Selection
3.3. SNPs Genotyping
| Primer Name | Primer Concentration | Primer Sequence |
|---|---|---|
| rs7404672F | 1 μM | TTTCCCTGCATTCCTACCAGCTA |
| rs7404672R | 1 μM | GCTTTTTGGTGAAAGAGCACTGG |
| rs9302456F | 1 μM | AGGTGCCAAAGTGCATCCTCTG |
| rs9302456R | 1 μM | GTGACTGCAGCTGCCTGGTACA |
| rs3087456F | 1 μM | TGTTGAAGGTTCCCCCAACAGA |
| rs3087456R | 1 μM | CCCAGCTCAGAAGCACACAGC |
| rs12928665F | 2 μM | CAGGGGTCTGGACAAGGAGGTT |
| rs12928665R | 2 μM | CGTGGAAGGCAACTGTGCTTTTA |
| rs12932187F | 1 μM | AGGGTGTGCCCCTGAAGAAGTC |
| rs12932187R | 1 μM | TTAAGGCTGCACCCAACCACAC |
| rs4774F | 1 μM | TATGGCCTGCAGGATCTGCTCT |
| rs4774R | 1 μM | GCCTTGCTCAGGCTCTGGAC |
| rs2296651F | 1 μM | GTCCCTGCTAGAAACTTGCTTGTTG |
| rs2296651R | 1 μM | TGGTAGCAGCACTGGGACAAAG |
| rs11622925F | 1 μM | CAGGGGTCTGGACAAGGAGGTT |
| rs11622925R | 1 μM | CGTGGAAGGCAACTGTGCTTTTA |
| rs4646287F | 1 μM | TCTCCCCAGTTTGGAAGGATGA |
| rs4646287R | 1 μM | AGAGTTTCCCAGCACCCACTCC |
| rs12882299F | 2 μM | CATTGCCACATGGCACATTCAC |
| rs12882299R | 2 μM | GCCATGCAAATTGGGCAGATTA |
| Probe Name | Probe Concentration | Probe Sequence |
|---|---|---|
| rs7404672FC | 1 μM | TTCCGCGTTCGGACTGATATCCTACCA |
| GCTAAGCCCCCTTTACTAC | ||
| rs7404672FT | 1 μM | TACGGTTATTCGGGCTCCTGTCCTACC |
| AGCTAAGCCCCCTTTACCAT | ||
| rs7404672FP | 2 μM | AATCCATCAGCAGGTCCAGGTTTTTTT |
| rs9302456FC | 1 μM | TCTCTCGGGTCAATTCGTCCTTGGATG |
| TCACTTGCTCTGCTCAGAGTCC | ||
| rs9302456FT | 1 μM | TGTTCGTGGGCCGGATTAGTGGATGTC |
| ACTTGCTCTGCTCAGAGTCT | ||
| rs9302456FP | 2 μM | TGCACYGACACAGGCATGGTTTTTTT |
| rs3087456RA | 1 μM | TACGGTTATTCGGGCTCCTGTCCACAC |
| TCCCTTAAGCCCTCACT | ||
| rs3087456RG | 1 μM | TTCCGCGTTCGGACTGATATCCACACT |
| CCCTTAAGCCCTCACC | ||
| rs3087456RP | 2 μM | ACACCTCTGAAATTAATTTCACTTCCT |
| TACTGTTTT | ||
| rs12928665RA | 1 μM | TACGGTTATTCGGGCTCCTGTGCCCGA |
| AAGTCTGACTTCTAGAACGTT | ||
| rs12928665RG | 1 μM | TTCCGCGTTCGGACTGATATGCCCGAA |
| AGTCTGACTTCTAGAACATC | ||
| rs12928665RP | 2 μM | TCGGTGCTGATACATGGTTCATACTTTT |
| rs12932187FC | 1 μM | TGTTCGTGGGCCGGATTAGTGCCCCTGA |
| AGAAGTCGTTTACATTGTC | ||
| rs12932187FG | 1 μM | TCTCTCGGGTCAATTCGTCCTTGCCCCT |
| GAAGAAGTCGTTTACATTGTG | ||
| rs12932187FP | 2 μM | GAGTCAATTTTCCTGGAGTGTACAATGTT |
| rs4774RC | 1 μM | TGTTCGTGGGCCGGATTAGTCGCTTCCAG |
| CTCCTCGATGC | ||
| rs4774RG | 1 μM | TCTCTCGGGTCAATTCGTCCTTCGCTTCC |
| AGCTCCTCGATGG | ||
| rs4774RP | 2 μM | CGTCTAGGATGAGCAGAACGCGTTTTT |
| rs2296651RA | 1 μM | TGTTCGTGGGCCGGATTAGTGGATGCCAAAAT |
| GTCCAACTCTGGTT | ||
| rs2296651RG | 1 μM | TCTCTCGGGTCAATTCGTCCTTGGATGCCAAA |
| ATGTCCAACTCTGATC | ||
| rs2296651RP | 2 μM | CACCATCCTCAATGTGGCCTTTTT |
| rs11622925FC | 1 μM | TTCCGCGTTCGGACTGATATGTGGCCACTGGC |
| GATGGTGC | ||
| rs11622925FT | 1 μM | TACGGTTATTCGGGCTCCTGTGTGGCCACTGG |
| CGATGGTGT | ||
| rs11622925FP | 2 μM | TGGGACATCTGGCCACTCACTTTTTTT |
| rs4646287RC | 1 μM | TTCCGCGTTCGGACTGATATAAGCAGAAATCA |
| GCAAGGGCACG | ||
| rs4646287RT | 1 μM | TACGGTTATTCGGGCTCCTGTAAGCAGAAATC |
| AGCAAGGGCACA | ||
| rs4646287RP | 2 μM | CTCCTGGAGACRCAGCACACTTTTTTTT |
| rs12882299RC | 1 μM | TCTCTCGGGTCAATTCGTCCTTTCTATTTTTA |
| TTGCTTTGTTGTCCAAGGTTG | ||
| rs12882299RT | 1 μM | TGTTCGTGGGCCGGATTAGTTCTATTTTTATT |
| GCTTTGTTGTCCAAGGCTA | ||
| rs12882299RP | 2 μM | TGATTGGTATAATTTTATTTTTGTTTTTTGCA |
3.4. Statistical Analysis
4. Results
4.1. H-W Equilibrium Test and LD Analyses
4.2. CIITA and NTCP Loci Polymorphisms and Chronic HBV Infection
| SNP | Healthy Subjects | Clearance Subjects | Chronic HBV Infection Subjects | Pa OR (95%CI) | Pb OR (95%CI) |
|---|---|---|---|---|---|
| rs7404672 | |||||
| CC | 98 | 121 | 171 | ||
| CT | 56 | 61 | 119 | 0.620 | 0.405 |
| TT | 16 | 17 | 15 | 1.11 (0.74 - 1.64) | 1.17 (0.80 - 1.71) |
| rs9302456 | |||||
| CC | 155 | 171 | 260 | ||
| CT | 13 | 27 | 44 | 0.015 | 0.356 |
| TT | 2 | 1 | 1 | 2.24 (1.17 - 4.29) | 1.28 (0.75 - 2.19) |
| rs3087456 | |||||
| GG | 144 | 164 | 250 | ||
| AG | 25 | 27 | 54 | 0.282 | 0.471 |
| AA | 1 | 8 | 1 | 1.34 (0.78 - 2.28) | 1.19(0.73 - 1.94) |
| rs12928665 | |||||
| GG | 71 | 80 | 114 | ||
| AG | 69 | 87 | 144 | 0.250 | 0.469 |
| AA | 30 | 32 | 47 | 1.26 (0.84 - 1.88) | 1.51(0.78 - 1.68) |
| rs12932187 | |||||
| CC | 62 | 72 | 107 | ||
| GC | 74 | 93 | 148 | 0.997 | 0.843 |
| GG | 34 | 34 | 50 | 0.99 (0.66 - 1.50) | 0.96 (0.65 - 1.41) |
| rs4774 | |||||
| GG | 126 | 152 | 229 | ||
| GC | 41 | 46 | 68 | 0.910 | 0.876 |
| CC | 3 | 1 | 8 | 0.97 (0.62 - 1.52) | 1.03 (0.67 - 1.59) |
| rs2296651 | |||||
| GG | 139 | 171 | 278 | 0.003 | 0.168 |
| AG | 19 | 28 | 27 | 0.41 (0.23 - 0.74) | 0.67 (0.37 - 1.19) |
| AA | 12 | 0 | 0 | ||
| rs11622925 | |||||
| CC | 130 | 155 | 222 | 0.361 | 0.252 |
| CT | 38 | 37 | 76 | 1.23 (0.79 - 1.94) | 1.29 (0.84 - 1.99) |
| TT | 2 | 7 | 7 | ||
| rs4646287 | |||||
| CC | 138 | 165 | 251 | 0.826 | 0.929 |
| CT | 29 | 30 | 51 | 0.95(0.58 - 1.57) | 1.02(0.63 - 1.67) |
| TT | 3 | 4 | 3 | ||
| rs12882299 | |||||
| TT | 56 | 65 | 71 | 0.003 | 0.011 |
| CT | 75 | 98 | 174 | 1.97 (1.27 - 3.07) | 1.71 (1.13 - 2.58) |
| CC | 39 | 36 | 60 |
aHealthy subjects versus chronic HBV infection subjects.
bClearance subjects versus chronic HBV infection subjects.
4.3. CIITA and NTCP Loci Polymorphisms with HBV Progression
| SNP | CHB | LC | HCC | Pa OR (95%CI) | Pb OR (95%CI) |
|---|---|---|---|---|---|
| rs7404672 | |||||
| CC | 89 | 43 | 39 | ||
| CT | 73 | 21 | 25 | 0.520 | 0.752 |
| TT | 7 | 4 | 4 | 0.78 (0.36 - 1.66) | 1.14 (0.50 - 2.58) |
| rs9302456 | |||||
| CC | 143 | 56 | 61 | ||
| CT | 26 | 11 | 7 | 0.091 | 0.515 |
| TT | 0 | 1 | 0 | 2.52 (0.86 - 7.37) | 1.57 (0.40 - 6.21) |
| rs3087456 | |||||
| GG | 140 | 54 | 56 | ||
| AG | 29 | 13 | 12 | 0.160 | 0.412 |
| AA | 0 | 1 | 0 | 2.04 (0.75 - 5.56) | 1.63 (0.50 - 5.27) |
| rs12928665 | |||||
| GG | 61 | 27 | 26 | ||
| AG | 85 | 28 | 31 | 0.572 | 0.876 |
| AA | 23 | 13 | 11 | 0.80 (0.37 - 1.72) | 1.06 (0.46 - 2.46) |
| rs12932187 | |||||
| CC | 57 | 23 | 27 | ||
| GC | 87 | 33 | 28 | 0.670 | 0.338 |
| GG | 25 | 12 | 13 | 0.83 (0.37 - 1.88) | 0.65 (0.27 - 1.55) |
| rs4774 | |||||
| GG | 126 | 51 | 52 | ||
| GC | 38 | 14 | 16 | 0.997 | 0.758 |
| CC | 5 | 3 | 0 | 1.00 (0.43 - 2.31) | 1.15 (0.46 - 2.86) |
| rs2296651 | |||||
| GG | 151 | 65 | 62 | 0.507 | 0.717 |
| AG | 18 | 3 | 6 | 0.54 (0.09 - 3.33) | 1.33 (0.28 - 6.21) |
| AA | 0 | 0 | 0 | ||
| rs11622925 | |||||
| CC | 123 | 50 | 49 | 0.881 | 0.069 |
| CT | 42 | 16 | 18 | 1.07 (0.43 - 2.65) | 2.41 (0.93 - 6.22) |
| TT | 4 | 2 | 1 | ||
| rs4646287 | |||||
| CC | 141 | 55 | 55 | 0.669 | 0.517 |
| CT | 27 | 12 | 12 | 1.23 (0.47 - 3.23) | 0.71 (0.24 - 2.03) |
| TT | 1 | 1 | 1 | ||
| rs12882299 | |||||
| TT | 35 | 19 | 17 | 0.137 | 0.498 |
| CT | 102 | 35 | 37 | 0.52 (0.22 - 1.23) | 0.71 (0.27 - 1.90) |
| CC | 32 | 14 | 14 |
aCHB versus LC.
bCHB versus HCC.

